Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05704933 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
A Early Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT05704933 is a Early Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 1 participants.
The verdict
NCT05704933, a Early Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to determine the safety and feasibility of giving a single dose of Nivolumab with Ipilimumab or Relatlimab in participants with brain metastases from melanoma who can undergo surgery for removal of their brain metastases 7- 10 days after receiving the study drug.
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Nivolumab + Relatlimab
- PROCEDURE Standard of Care Craniotomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-06-06 |
| Est. Completion | 2024-08-20 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05704933
The ClinicalTrials.gov registry entry for NCT05704933 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Nivolumab is the first listed.
NCT05704933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05704933 about?
NCT05704933 is a clinical study titled "Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases". The purpose of this pilot study is to determine the safety and feasibility of giving a single dose of Nivolumab with Ipilimumab or Relatlimab in participants with brain metastases from melanoma who can undergo surgery for removal of their brain metastases 7- 10 days after receiving the study drug.
What is the current status of trial NCT05704933?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2023-06-06. Estimated completion is 2024-08-20.
What interventions are being tested in trial NCT05704933?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Nivolumab + Relatlimab (DRUG), Standard of Care Craniotomy (PROCEDURE).
Who is sponsoring clinical trial NCT05704933?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.